 Our study found that higher levels of systemic inflammation are associated with an increased risk of low muscle mass in a large population. This suggests that anti-inflammation therapies could be beneficial for those at risk of developing low muscle mass. This article was authored by Lin Xia, Liang Zhong, Dan Zhong, and others.